Abstract Number: 2126 • 2019 ACR/ARP Annual Meeting
Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer a high susceptibility to infection, and many inflammatory cytokines are prognostic in RA, but currently the role of cytokines in identifying infection individuals…Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…Abstract Number: 511 • 2019 ACR/ARP Annual Meeting
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated efficacy and safety in patients with rheumatoid arthritis (RA) as monotherapy and in combination with conventional…Abstract Number: 816 • 2019 ACR/ARP Annual Meeting
The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts
Background/Purpose: Mechanisms involved in joint patterning of rheumatic diseases remain unknown. The long non-coding RNA HOTAIR is exclusively expressed in synovial fibroblasts (SF) from lower…Abstract Number: 999 • 2019 ACR/ARP Annual Meeting
Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy
Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease characterized by inflammation of the synovial tissue of the joints, which if not controlled early…Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…Abstract Number: 2162 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)
Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…Abstract Number: 6 • 2019 ACR/ARP Annual Meeting
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and…Abstract Number: 513 • 2019 ACR/ARP Annual Meeting
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…Abstract Number: 817 • 2019 ACR/ARP Annual Meeting
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia, consisting of type A macrophage-like synoviocytes and type B fibroblast-like synoviocytes (FLS).…Abstract Number: 1000 • 2019 ACR/ARP Annual Meeting
RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis
Background/Purpose: Nuclear factor-kappaB (NF-kappaB) and extracellular-signal-regulated kinase (ERK) have been implicated as a therapeutic target for the treatment of rheumatoid arthritis (RA). Raf kinase inhibitory…Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
- « Previous Page
- 1
- …
- 167
- 168
- 169
- 170
- 171
- …
- 188
- Next Page »